|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006837,
umls-concept:C0012655,
umls-concept:C0016277,
umls-concept:C0021311,
umls-concept:C0026809,
umls-concept:C0087111,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1515655,
umls-concept:C1533691,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1996-6-10
|
|
pubmed:abstractText |
A series of fluconazole-susceptible and-fluconazole resistant Candida albicans fungal isolates were used to infect mice intravenously. Mice were treated with varying doses of fluconazole beginning one day after infection. For all of the 6 fluconazole-susceptible isolates, fluconazole was highly effective at <0.25 mg/kg of body weight twice daily. By contrast, fluconazole was less effective in at least 6 of 10 fluconazole-resistant isolates and was ineffective at > or = 40 mg/kg twice daily in 4 fluconazole-resistant isolates. Although the correlation is not precise, in vitro susceptibility testing of C. albicans can predict in vivo response to fluconazole.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-1308663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-1520786,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-1542320,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-1669837,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-1823784,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-1922232,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-2073120,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-2749102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-3196127,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-7288218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-7722785,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-7935701,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-8110924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-8161633,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-8239613,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-8285632,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-8335986,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8619566-8442620
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
39
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2197-200
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Fluconazole treatment of Candida albicans infection in mice: does in vitro susceptibility predict in vivo response?
|
|
pubmed:affiliation |
Division of Infectious Diseases (111F), Audie Murphy VA Hospital, San Antonio, TX 78284, USA.
|
|
pubmed:publicationType |
Journal Article
|
